Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 17/20 | 0.51 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810274 | 1.00 | CACNA1H (0.51) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL1810269 | 1.00 | CACNA1H (0.51) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL11899952 | 0.93 | CACNA1H (0.51) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL6903541 | 0.93 | CACNA1H (0.51) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL11899956 | 0.93 | CACNA1H (0.51) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL17975595 | 0.91 | CACNA1H (0.52) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL12076529 | 0.91 | CACNA1H (0.52) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL11899284 | 0.90 | CACNA1I (0.52) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL1807696 | 0.90 | CACNA1I (0.52) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 | |
| SCHEMBL11899285 | 0.90 | CACNA1I (0.52) | CACNA1HCACNA1ICACNA1GCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987310-B2 | Heterocycle amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | claimed |
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | claimed |
| US-8987310-B2 | Heterocycle amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2493297-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | disclosed |
| WO-2011053542-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885CACNA1I 3/4885CACNA1G 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.